MTNR1A and major depressive disorder: Agomelatine, an MT1 and MT2 agonist and a 5-HT2C and 5-HT2B serotonin receptor antagonist, is used to treat MDD [268] and has been shown to have positive phase-shifting properties, such as inducing sleep phase advancement, body temperature decline, and melatonin onset.